Early regression of left ventricular hypertrophy after treatment with esmolol in an experimental rat model of primary hypertension.
Certain β-adrenergic blockers have proven useful in the regression of ventricular remodeling when administered as long-term treatment. However, early regression of left ventricular hypertrophy (LVH) has not been reported, following short-term administration of these drugs. We tested the hypothesis that short-term administration of the cardioselective β-blocker esmolol induces early regression of LVH in spontaneously hypertensive rats (SHR). Fourteen-month-old male SHRs were treated i.v. with vehicle (SHR) or esmolol (SHR-E) (300 μg kg(-1) min(-1)). Age-matched vehicle-treated male Wistar-Kyoto (WKY) rats served as controls. After 48 h, left ventricular morphology and function were assessed using M-mode echocardiograms (left ventricular mass index (LVMI), ejection fraction and transmitral Doppler (early-to-atrial filling velocity ratio (E/A), E-wave deceleration time (Edec time)). The standardized uptake value (SUV) was applied to evaluate FDG (2-deoxy-2[18F]fluoro-D-glucose) uptake by the heart using PET/CT. Left ventricular subendocardial and subepicardial biopsies were taken to analyze changes in cross-sectional area (CSA) of left ventricular cardiomyocytes and the fibrosis was expressed as collagen volume fraction (CVF). LVMI was lower in SHR-E with respect to SHR (P=0.009). There were no significant differences in EF, E/A ratio or Edec time in SHR-E compared with SHR (P=0.17, 0.55 and P=0.80, respectively). PET acquisitions in SHR-E showed lower (18)F-FDG uptake than SHR (P=0.003). Interestingly, there were no significant differences in SUV in either SHR-E or WKY (P=0.63). CSA in subendocardial and subepicardial regions was minor in SHR-E with respect to SHR (P<0.001), and there were no significant differences in CVF between both groups. Esmolol reverses early LVH in the SHR model of stable compensated ventricular hypertrophy. This is the first study to associate early regression of LVH with administration of a short-term β-blocker.
Department of Anesthesiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. begoquinti@gmail.com
Begoña
B
Quintana-Villamandos
María Jesús
MJ
Delgado-Martos
Jose Javier
JJ
Sánchez-Hernández
Jose Juan
JJ
Gómez de Diego
María del Carmen
Mdel C
Fernández-Criado
Fernando
F
Canillas
Antonia
A
Martos-Rodríguez
Emilio
E
Delgado-Baeza
D058671:Adrenergic beta-1 Receptor Antagonists / Q000008:administration & dosage*; D000818:Animals; D004353:Drug Evaluation, Preclinical; D019788:Fluorodeoxyglucose F18; D006973:Hypertension / Q000150:complications*; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D011412:Propanolamines / Q000008:administration & dosage*; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D014463:Ultrasonography
D058671:Adrenergic beta-1 Receptor Antagonists; D011412:Propanolamines; D019788:Fluorodeoxyglucose F18; C036604:esmolol